Subsequently, other drugs such as Novos Victoza (liraglutide, approved in 2010), AstraZenecas Bydureon (exenatide, 2012), GSKs Tanzeum (albiglutide, 2014), Lillys Trulicity (dulaglutide, 2014) and Novos Ozempic (semaglutide, 2017) and Rybelsus (oral semaglutide, 2019) were approved
Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine 384 (11): 9891002
Trends also show interest in oral vs
Melanotan 2 activates MC4R in addition to MC1R, and MC4R signaling drives erectile response, libido and satiety
No (BMI under 27): MassHealth will not cover GLP-1 medications